How does ICER plan to determine if health plans offer fair access to pharmaceuticals? I summarized their approach last year, as stated in their white paper titled “Cornerstones of “Fair” Drug Coverage: Appropriate Cost Allocation and Use Management Policies for Pharmaceuticals. ” Last month, final protocol for their “Assessment of Equitable Access Barriers”.“. While the approach is consistent with their previous protocol and white paper, not all criteria in this white paper are evaluated. What criteria does ICER evaluate? Below I have summarized the criteria that ICER plans to include and exclude in its “fair access” assessment.